对PYY3-36的变异选导致具有优越Y2受体选择性的强效长效PYY类似物
Søren Østergaard1, Carsten Jessen1, Johan F Paulsson2
1Global Research Technologies, Novo Nordisk A/S, Novo Research Park, 2760 Måløv, Denmark.
Science translational medicine
|March 26, 2025
概括
研究人员开发了长期作用的YY (PYY3-36) 类似物用于糖尿病和肥胖症. 这些新型PYY类型显示出改善葡萄糖控制和减肥,其中一个候选者进入临床试验.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢研究研究 代谢研究
背景情况:
- YY (PYY3-36) 对于调节食物摄入量和葡萄糖平衡至关重要.
- 本地PYY3-36的半衰期很短,对治疗开发的选择性不足.
- 向Y2受体是PYY模拟疗效的关键.
研究的目的:
- 开发具有长效,高度选择性的PYY3-36类似物.
- 为了增强PYY3-36的功效,选择性和稳定性.
- 在糖尿病和肥胖的临床前模型中评估模拟疗效.
主要方法:
- 对PYY3-36进行变异选,以确定关键氨基酸.
- 脂肪二酸衍生制造以制造长期起作用的类似物.
- 在糖尿病小鼠和ZSF1大鼠和饮食诱导的肥胖小鼠模型中进行临床前测试.
主要成果:
- 开发了高度选择性的,长期起作用的PYY3-36类似物,准Y2受体.
- 同类药物改善了糖尿病小鼠的葡萄糖代谢.
- 与GLP-1激动剂的联合治疗在动物模型中显示出优异的血糖降低和体重减轻.
- PYY1875类似物已进入针对肥胖的临床试验.
结论:
- 变异选和脂肪二酸衍生物化是开发PYY类似物的有效策略.
- 长效PYY类似物对治疗糖尿病和肥胖有希望.
- PYY1875代表了肥胖管理的潜在新疗法候选者.
相关概念视频
Dose-Response Relationship: Selectivity and Specificity
10.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.8K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.2K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
4.2K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.9K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.9K


